Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 4 Changes in risk of estrogen receptor-negative breast cancer by race with inclusion of single-nucleotide polymorphisms in CYP24A1

From: Variants in the vitamin D pathway, serum levels of vitamin D, and estrogen receptor negative breast cancer among African-American women: a case-control study

Model Variable Adjusted OR (95% CI) Pvalue
Base model Race (AA versus EA) 1.53 (1.06-2.22) 0.02
Base model + SNPs Race (AA versus EA) 1.20 (0.80-1.79) 0.38
  rs2209314 (AG/GG versus AA) 0.57 (0.36-0.89) 0.01
  rs2762941 (AG versus AA) 1.47 (0.96-2.25) 0.04
  rs2762941 (GG versus AA) 1.88 (1.15-3.06)  
  1. Covariates included in the base model were age at diagnosis, body mass index, family history of breast cancer, education, and race. Odds ratio (OR) and 95% confidence interval (CI) for race after adjustment for other covariates are shown. Based on this model, seven single-nucleotide polymorphisms (SNPs) in CYP24A1 (rs927650, rs1570669, rs2209314, rs3787555, rs2762941, rs4809959, and rs2585428) and one SNP in VDR (rs3819545) that were associated with estrogen receptor-negative (ER-) breast cancer risk in either African-American (AA) or European-American (EA) women were entered and backward-selected. Two SNPs, rs2209314 and rs2762941, remained in the final model with a P value of less than 0.05. ORs and 95% CIs for race and the two SNPs are shown.